Acute Inpatient Treatment for Multiple Sclerosis Relapse
For acute MS relapses requiring inpatient management, administer high-dose intravenous methylprednisolone 1000 mg daily for 3-7 days, followed by an oral prednisone taper if needed; for steroid-refractory cases, proceed to plasma exchange (PLEX) as second-line therapy.
Initial Assessment and Treatment Initiation
When a patient presents with an acute MS relapse (new neurological symptoms or worsening existing symptoms persisting >24 hours, not attributable to infection, fever, or overexertion), immediate high-dose corticosteroid therapy is the standard of care.
First-Line: High-Dose Intravenous Methylprednisolone
The FDA-approved regimen is methylprednisolone 1000 mg IV daily 1. The evidence supports:
- Duration: 3-7 days is effective, with most protocols using 3-5 days 2, 1, 3
- Administration: Infuse over at least 30 minutes to several minutes to minimize cardiac arrhythmia risk 1
- Historical validation: The classic regimen of 160 mg daily for 1 week followed by 64 mg every other day for 1 month has proven effective 1, though shorter 3-5 day courses are now standard
The evidence strongly favors IV methylprednisolone over oral ACTH, with faster clinical improvement demonstrated in randomized trials 4, 5. A 1987 double-blind trial showed highly significant effects (p<0.001) with 500 mg IV daily for 5 days, with improvements evident at both 1 and 4 weeks 5.
Oral Alternative (When IV Access is Problematic)
Oral methylprednisolone 1000-1250 mg daily for 3 days is non-inferior to IV administration 3. The COPOUSEP trial definitively established that oral high-dose methylprednisolone achieves equivalent disability improvement at 28 days (81% vs 80% response rate, absolute difference 0.5%, 90% CI -9.5 to 10.4) 3.
Consider oral therapy when:
- Poor venous access exists
- Home infusion is unavailable
- Patient preference strongly favors oral route
- COVID-19 or infection risk necessitates avoiding hospital exposure 6
Caveat: Insomnia occurs more frequently with oral administration (77% vs 64%) 3.
Oral Taper Following IV Pulse Therapy
An oral prednisone taper is optional and not universally required 1, 3. When used:
- Start prednisone 60-80 mg daily (or 1 mg/kg/day)
- Taper gradually over 2-4 weeks
- Monitor for relapse during taper
- The evidence does not support that tapering prevents relapse better than abrupt discontinuation in short courses 1
The FDA label notes that for MS specifically, 200 mg prednisolone daily for 1 week followed by 80 mg every other day for 1 month has been effective (equivalent to 160 mg then 64 mg methylprednisolone) 7, though this extended regimen is less commonly used in current practice.
Steroid-Refractory Disease: Second-Line Therapy
If no improvement occurs after 5-7 days of high-dose IV methylprednisolone, proceed to plasma exchange (PLEX) 2. The evidence base for PLEX in steroid-refractory MS relapses comes from systematic reviews showing:
- PLEX is effective for severe relapses not responding to corticosteroids
- Typically administered as 5-7 exchanges over 10-14 days
- Earlier initiation (within 3 months of relapse onset) yields better outcomes
Alternative Considerations for Refractory Cases
While not extensively studied in MS specifically, the immunotherapy toxicity literature provides guidance on escalating immunosuppression:
- IVIG (2 g/kg IV over 5 days, or 0.4 g/kg/day) may be considered 8
- Rituximab has been used in severe cases, particularly for neuromyelitis optica spectrum disorder overlap 2
Monitoring and Safety
Critical Safety Considerations
Cardiac monitoring is essential during rapid IV administration 1:
- Bradycardia and arrhythmias reported with doses >0.5 g administered over <10 minutes
- Always infuse over ≥30 minutes for 1000 mg doses
- Monitor vital signs during infusion
Baseline and Follow-up Testing
Before initiating therapy, ensure:
- Infection has been ruled out (fever, elevated WBC, urinalysis)
- Blood glucose monitoring (especially in diabetics or pre-diabetics)
- Blood pressure monitoring
- Consider GI prophylaxis if ulcer history or significant dyspepsia 1
Specific Populations
Pediatric dosing: 30 mg/kg/day (maximum 1000 mg/day) for 3-5 days 9, 1
Pregnancy: Methylprednisolone crosses the placenta but is generally considered acceptable for acute relapses when benefits outweigh risks
Common Pitfalls to Avoid
Inadequate dosing: Using <500 mg/day is suboptimal; the evidence supports ≥1000 mg daily 3, 5
Treating pseudorelapses: Always exclude infection, hyperthermia, and metabolic derangements before treating
Prolonged high-dose therapy: Courses >7 days increase adverse effects without additional benefit for acute relapses
Delaying PLEX: If no response by day 5-7 of steroids, don't continue steroids indefinitely—escalate to PLEX
Mixing with incompatible solutions: Methylprednisolone sodium succinate should not be mixed with other solutions; use only bacteriostatic water for reconstitution 1
Disposition and Follow-up
- Clinical reassessment at 1 week: Expect improvement in EDSS scores 3, 5
- Follow-up at 4 weeks: Sustained improvement should be evident 5
- MRI surveillance: Not routinely required for treatment response, but consider if clinical response is unclear
- Disease-modifying therapy: Ensure patient is on or being initiated on appropriate long-term DMT to prevent future relapses
The evidence consistently demonstrates that high-dose corticosteroids accelerate recovery from acute MS relapses, though they do not alter long-term disability progression 4. The goal is rapid symptom control to minimize acute disability and facilitate return to baseline function.